French Martyn A, Abudulai Laila N, Fernandez Sonia
School of Pathology and Laboratory Medicine, University of Western Australia, Perth 6009, Australia.
Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth 6000, Australia.
Vaccines (Basel). 2013 Aug 9;1(3):328-42. doi: 10.3390/vaccines1030328.
The development of vaccines to treat and prevent human immunodeficiency virus (HIV) infection has been hampered by an incomplete understanding of "protective" immune responses against HIV. Natural control of HIV-1 infection is associated with T-cell responses against HIV-1 Gag proteins, particularly CD8⁺ T-cell responses restricted by "protective" HLA-B alleles, but other immune responses also contribute to immune control. These immune responses appear to include IgG antibodies to HIV-1 Gag proteins, interferon-a-dependant natural killer (NK) cell responses and plasmacytoid dendritic cell (pDC) responses. Here, it is proposed that isotype diversification of IgG antibodies against HIV-1 Gag proteins, to include IgG2, as well as IgG3 and IgG1 antibodies, will broaden the function of the antibody response and facilitate accessory cell responses against HIV-1 by NK cells and pDCs. We suggest that this should be investigated as a vaccination strategy for HIV-1 infection.
对人类免疫缺陷病毒（HIV）感染进行治疗和预防的疫苗研发工作，一直受到对HIV“保护性”免疫反应认识不全面的阻碍。HIV-1感染的自然控制与针对HIV-1 Gag蛋白的T细胞反应有关，特别是受“保护性”HLA-B等位基因限制的CD8⁺ T细胞反应，但其他免疫反应也有助于免疫控制。这些免疫反应似乎包括针对HIV-1 Gag蛋白的IgG抗体、干扰素-α依赖的自然杀伤（NK）细胞反应和浆细胞样树突状细胞（pDC）反应。在此，有人提出，针对HIV-1 Gag蛋白的IgG抗体的同种型多样化，包括IgG2以及IgG3和IgG1抗体，将拓宽抗体反应的功能，并促进NK细胞和pDC针对HIV-1的辅助细胞反应。我们建议应将此作为HIV-1感染的一种疫苗接种策略进行研究。
